US85205L1070 - Common Stock
SPRINGWORKS THERAPEUTICS INC
NASDAQ:SWTX (5/6/2024, 7:00:00 PM)
After market: 46.32 0 (0%)46.32
+1.21 (+2.68%)
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 227 full-time employees. The company went IPO on 2019-09-13. The firm is focused on acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. The company has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. Its product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI), in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.
SPRINGWORKS THERAPEUTICS INC
100 Washington Blvd
Stamford CONNECTICUT 06902
P: 12038839490
CEO: Saqib Islam
Employees: 227
Website: https://www.springworkstx.com/
SWTX stock results show that SpringWorks Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat...
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO®...
Here you can normally see the latest stock twits on SWTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: